The FDA has granted premarket approval to a test that assesses a patient’s viral load of cytomegalovirus (CMV), the most common and important viral infection in recipients of solid organ transplants.
The fully automated COBAS AmpliPrep/COBAS TaqMan CMV Test, from Roche, is the first FDA-approved laboratory test for use in quantifying CMV DNA in human plasma specimens.
From the September 01, 2012 Issue of Renal and Urology News
Next post in News in Brief
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.